BioCentury
ARTICLE | Company News

Arena, Eisai deal

January 6, 2017 10:06 PM UTC

Arena amended its licensing agreement with Eisai, granting the Japanese pharma worldwide development and commercialization rights to obesity drug Belviq lorcaserin. Eisai will be responsible for all development and commercialization costs. Eisai already held rights to Belviq in most markets worldwide. The companies first partnered in 2010 and expanded the deal in 2013 to add more territories. Arena will transfer to Eisai its Belviq rights under existing territorial deals with Ildong Pharmaceutical Co. Ltd. (KSE:000230, Seoul, South Korea), the Abic Marketing Ltd. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA, Petah Tikva, Israel) and CY Biotech Co. Ltd. (Beijing, China). Arena granted South Korean rights to Ildong, Israeli rights to Abic and Taiwanese rights to CY Biotech. Belviq is a serotonin (5-HT2C) receptor agonist...